Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.
Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep2-2026a1000aau. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/29378307/
Phosphatidylethanol and Self-Reported Alcohol Intake to Subclassify Individuals at Risk of Steatotic Liver Disease: An Analysis of Data From a Prospective Cohort Study https://pubmed.ncbi.nlm.nih.gov/40945520/
The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test https://pubmed.ncbi.nlm.nih.gov/9738608/
Elevated ALT/AST Ratio as a Marker for NAFLD Risk and Severity: Insights From a Cross-Sectional Analysis in the United States https://pubmed.ncbi.nlm.nih.gov/39253584/
Podden och tillhörande omslagsbild på den här sidan tillhör
Medscape. Innehållet i podden är skapat av Medscape och inte av,
eller tillsammans med, Poddtoppen.